标题
Advances and Unmet Needs in the Therapeutics of Bone Fragility
作者
关键词
-
出版物
Frontiers in Endocrinology
Volume 9, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-09-06
DOI
10.3389/fendo.2018.00505
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Abstracts of the ECTS Congress 2018
- (2018) CALCIFIED TISSUE INTERNATIONAL
- Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study
- (2018) Michael R McClung et al. JOURNAL OF BONE AND MINERAL RESEARCH
- FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab
- (2018) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial
- (2018) Piet Geusens et al. JOURNAL OF BONE AND MINERAL RESEARCH
- ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
- (2018) Henry G Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial
- (2018) Lee Shepstone et al. LANCET
- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
- (2018) David L Kendler et al. LANCET
- Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
- (2017) Steven R Cummings et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
- (2017) Athanasios D Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study
- (2017) David W Dempster et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Response to Letter: Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation
- (2017) Olivier Lamy et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
- (2017) Bente L Langdahl et al. LANCET
- Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
- (2017) Kenneth G. Saag et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial
- (2017) J. P. Bilezikian et al. OSTEOPOROSIS INTERNATIONAL
- Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study
- (2017) K. H. Rubin et al. OSTEOPOROSIS INTERNATIONAL
- Osteoporosis treatment: recent developments and ongoing challenges
- (2017) Sundeep Khosla et al. Lancet Diabetes & Endocrinology
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
- (2017) Henry G Bone et al. Lancet Diabetes & Endocrinology
- Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats
- (2016) Hila Bahar et al. CALCIFIED TISSUE INTERNATIONAL
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis
- (2016) Paul D. Miller et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Crisis in the Treatment of Osteoporosis
- (2016) Sundeep Khosla et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Abaloparatide Is an Anabolic, but Does It Spare Resorption?
- (2016) T. John Martin et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study)
- (2016) J. N. Tsai et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
- (2016) P. D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis
- (2016) Felicia Cosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Co-administration of Antiresorptive and Anabolic Agents: A Missed Opportunity
- (2015) Ego Seeman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
- (2015) Dennis M. Black et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab
- (2015) Michael S Ominsky et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis
- (2015) Benjamin Z. Leder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
- (2015) Benjamin Z Leder et al. LANCET
- Short-term and long-term effects of osteoporosis therapies
- (2015) Ian R. Reid Nature Reviews Endocrinology
- Bone remodeling markers: so easy to measure, so difficult to interpret
- (2015) E. Seeman et al. OSTEOPOROSIS INTERNATIONAL
- Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports
- (2015) B. Aubry-Rozier et al. OSTEOPOROSIS INTERNATIONAL
- Multiple clinical vertebral fractures following denosumab discontinuation
- (2015) A. D. Anastasilakis et al. OSTEOPOROSIS INTERNATIONAL
- Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics
- (2015) A. W. Popp et al. OSTEOPOROSIS INTERNATIONAL
- Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report
- (2015) S. K. Ramchand et al. OSTEOPOROSIS INTERNATIONAL
- Bone cell-independent benefits of raloxifene on the skeleton: A novel mechanism for improving bone material properties
- (2014) Maxime A. Gallant et al. BONE
- Cortical Porosity Identifies Women With Osteopenia at Increased Risk for Forearm Fractures
- (2014) Yohann Bala et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Cortical Bone: A Challenging Geography
- (2014) Roger Zebaze et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate
- (2014) J. P. Brown et al. OSTEOPOROSIS INTERNATIONAL
- A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images
- (2013) R. Zebaze et al. BONE
- Differing effects of denosumab and alendronate on cortical and trabecular bone
- (2013) Roger M. Zebaze et al. BONE
- Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study
- (2013) C. Roux et al. BONE
- Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial
- (2013) Andrew Grey et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
- (2013) Elizabeth Shane et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams
- (2013) I. R. Reid et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
- (2013) Joy N Tsai et al. LANCET
- An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®
- (2013) J.-M. Kaufman et al. OSTEOPOROSIS INTERNATIONAL
- Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody
- (2011) Paul J. Kostenuik et al. BONE
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
- (2011) Dennis M Black et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
- (2011) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate
- (2010) Matthew R. Allen et al. BONE
- Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate
- (2010) Ego Seeman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
- (2010) Ian R Reid et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis
- (2010) Felicia Cosman et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial
- (2010) Paul D. Miller et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study
- (2010) Roger MD Zebaze et al. LANCET
- Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis
- (2010) H. M. Macdonald et al. OSTEOPOROSIS INTERNATIONAL
- Potential mediators of the mortality reduction with zoledronic acid after hip fracture
- (2009) Cathleen S Colón-Emeric et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
- (2008) Paul D. Miller et al. BONE
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
- (2008) R. G. G. Russell et al. OSTEOPOROSIS INTERNATIONAL
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started